AMG 510 (Sotorasib)
KRAS G12C Inhibitor
AMG 510 (Sotorasib) is a selective KRAS G12C inhibitor that specifically targets cancer cells with KRAS G12C mutations, which are found in approximately 13% of non-small cell lung cancers.
How It Works
AMG 510 works by irreversibly binding to the KRAS G12C mutant protein, locking it in an inactive state. This prevents the protein from sending growth signals to cancer cells, effectively stopping tumor growth and potentially shrinking existing tumors.
Clinical Trial Results
Side Effects Profile
Personalized for Your Profile
Based on your medical history, you may have increased risk of liver-related side effects due to previous chemotherapy exposure.
Common Side Effects
- Diarrhea (42%)
- Fatigue (24%)
- Nausea (19%)
- Decreased appetite (14%)
Serious Side Effects
- Liver enzyme elevation (7%)
- Pneumonitis (3%)
- QT prolongation (2%)
How to Access This Treatment
Confirm KRAS G12C Mutation
Request tumor biomarker testing from your oncologist if not already done
Expected timeframe: 1-2 weeksClinical Trial Screening
Contact trial sites near you to begin screening process
Expected timeframe: 2-3 weeksInsurance Pre-authorization
Work with your healthcare team to submit insurance approval
Expected timeframe: 2-4 weeksTreatment Initiation
Begin treatment at approved clinical center
Expected timeframe: 1 weekQuick Facts
Eligibility Criteria
- KRAS G12C mutation confirmed by tumor testing
- Advanced or metastatic non-small cell lung cancer
- Previous treatment with at least one systemic therapy
- ECOG performance status 0-2
- Adequate organ function
Related Clinical Trials
LUMAKRAS in Advanced Solid Tumors
NCT04380753
Take Action
Demo Notice: Treatment information shown is for demonstration purposes. Real clinical data integration and AI analysis are not yet implemented.
© 2025 DeepConnect AI. All rights reserved. This content is proprietary and protected by copyright law.